ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

3SBio and Lunan Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

3SBioLunan Pharmaceutical Group
studies on the registry10739
open to participants now4619
phase 3 studies under way1110
reach primary completion within a year164
programswith a study of their own in two years2720

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phase3SBioLunan Pharmaceutical Group
Phase 1

3SBio: 11 of its 27 programs at phase 1

  1. 3SC009phase 1
  2. existing formulations of 611phase 1
  3. HBT-708phase 1
  4. new formulations of 611phase 1
  5. SSGJ-709phase 1

and 6 more — sign in to see them all

41%

Lunan Pharmaceutical Group: 8 of its 20 programs at phase 1

  1. F182112phase 1
  2. LNF2007phase 1
  3. LNF2105phase 1
  4. Dronedaroneno phase
  5. Budesonideno phase

and 3 more — sign in to see them all

40%
Phase 2

3SBio: 11 of its 27 programs at phase 2

  1. Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705phase 2
  2. SSGJ-706phase 2
  3. SPGL008phase 2
  4. SSS17phase 2
  5. SSGJ-613phase 2

and 6 more — sign in to see them all

41%

Lunan Pharmaceutical Group: 4 of its 20 programs at phase 2

  1. F182112+CD38phase 2
  2. mosapridephase 2
  3. Vonorasan fumarate injection1phase 2
  4. Vonorasan fumarate injection2phase 2
20%
Phase 3

3SBio: 5 of its 27 programs at phase 3

  1. camtarkibartphase 3
  2. 608phase 3
  3. tivunatamigphase 3
  4. Clascoteronephase 3
  5. Minoxidilphase 3
19%

Lunan Pharmaceutical Group: 8 of its 20 programs at phase 3

  1. rulonilimabphase 3
  2. Beclomethasonephase 3
  3. Cetirizinephase 3
  4. Diphenhydraminephase 3
  5. F027phase 3

and 3 more — sign in to see them all

40%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
3SBio11 readouts · 2 phase 3·

3SBio, Dec ’26: 5 programs whose next study reaches primary completion

  1. Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705phase 2 · Dec 0 · NCT06390774
  2. SSGJ-706phase 2 · Dec 0 · NCT07233850
  3. SSS55phase 1 · Dec 0 · NCT07058779
  4. SSS68phase 1 · Dec 0 · NCT07606976
  5. xeloxphase 2 · Dec 0 · NCT07233850

3SBio, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. 608phase 3 · Jan 14 · NCT07261644
·

3SBio, Mar ’27: 1 program whose next study reaches primary completion

  1. SSS59phase 1 · Mar 1 · NCT06944444
····

3SBio, Aug ’27: 2 programs whose next study reaches primary completion

  1. SSGJ-613phase 2 · Aug 11 · NCT07708181
  2. SSGJ-716phase 1 · Aug 29 · NCT07693738

3SBio, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. camtarkibartphase 3 · Sep 0 · NCT07767253
  2. SSGJ-709phase 1 · Sep 30 · NCT07016490
·
Lunan Pharmaceutical Group4 readouts · 1 phase 3·

Lunan Pharmaceutical Group, Dec ’26: 1 program whose next study reaches primary completion

  1. LNF2007phase 1 · Dec 0 · NCT06752447
·

Lunan Pharmaceutical Group, Feb ’27: 2 programs whose next study reaches primary completion

  1. Vonorasan fumarate injection1phase 2 · Feb 0 · NCT06783257
  2. Vonorasan fumarate injection2phase 2 · Feb 0 · NCT06783257
···

Lunan Pharmaceutical Group, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Isosorbidephase 3 · Jun 30 · NCT06765993
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

3SBio

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 0

None

Lunan Pharmaceutical Group

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 8 in all. A program counts in each condition its studies name most.

Condition3SBioLunan Pharmaceutical Group
Carcinoma, Non-Small-Cell Lungboth · compare here

3SBio in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. tivunatamigphase 3
  2. SSGJ-706phase 2
  3. SPGL008phase 2
  4. xeloxphase 2

Their studies: 3SBio’s studies of Carcinoma, Non-Small-Cell Lung in search

Lunan Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 1 program

  1. rulonilimabphase 3

Their studies: Lunan Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Colorectal Neoplasmsboth · compare here

3SBio in Colorectal Neoplasms: 3 programs

  1. tivunatamigphase 3
  2. SSGJ-706phase 2
  3. xeloxphase 2

Their studies: 3SBio’s studies of Colorectal Neoplasms in search

Lunan Pharmaceutical Group in Colorectal Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Breast Neoplasmsboth · compare here

3SBio in Breast Neoplasms: 2 programs

  1. SSGJ-612phase 2
  2. HER2-targeted ADCphase 2

Their studies: 3SBio’s studies of Breast Neoplasms in search

Lunan Pharmaceutical Group in Breast Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Breast Neoplasms in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

3SBio in Pulmonary Disease, Chronic Obstructive: 1 program

  1. camtarkibartphase 3

Their studies: 3SBio’s studies of Pulmonary Disease, Chronic Obstructive in search

Lunan Pharmaceutical Group in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. Beclomethasonephase 3
  2. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Pulmonary Disease, Chronic Obstructive in search

Colitis, Ulcerativeboth · compare here

3SBio in Colitis, Ulcerative: 1 program

  1. 627phase 2

Their studies: 3SBio’s studies of Colitis, Ulcerative in search

Lunan Pharmaceutical Group in Colitis, Ulcerative: 1 program

  1. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Colitis, Ulcerative in search

Lupus Erythematosus, Systemicboth · compare here

3SBio in Lupus Erythematosus, Systemic: 1 program

  1. 626phase 2

Their studies: 3SBio’s studies of Lupus Erythematosus, Systemic in search

Lunan Pharmaceutical Group in Lupus Erythematosus, Systemic: 1 program

  1. F182112phase 1

Their studies: Lunan Pharmaceutical Group’s studies of Lupus Erythematosus, Systemic in search

Small Cell Lung Carcinomaboth · compare here

3SBio in Small Cell Lung Carcinoma: 1 program

  1. tivunatamigphase 3

Their studies: 3SBio’s studies of Small Cell Lung Carcinoma in search

Lunan Pharmaceutical Group in Small Cell Lung Carcinoma: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Small Cell Lung Carcinoma in search

Stomach Neoplasmsboth · compare here

3SBio in Stomach Neoplasms: 1 program

  1. xeloxphase 2

Their studies: 3SBio’s studies of Stomach Neoplasms in search

Lunan Pharmaceutical Group in Stomach Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Stomach Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: 3SBio 6 of 27 · Lunan Pharmaceutical Group 8 of 20 programs (13 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.